

2nd International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation

November 5–6, 2012

Natcher Conference Center, Bethesda, MD

Monday, November 5, 2012

8:00AM-8:15AM **WELCOME AND INTRODUCTIONS**

Michael Bishop, University of Chicago
Sergio Giralt, Memorial Sloan-Kettering Cancer Center
Nicolaus Kröger, University of Hamburg
Alan Wayne, National Cancer Institute

SESSION 1: BIOLOGY OF RELAPSE AFTER STEM CELL TRANSPLANTATION

8:15AM – 9:45AM

“Lymphocyte Homeostasis: Implications for the Prevention and Treatment of Relapse”

Ronald Gress, National Cancer Institute

“Natural Killer Cell Biology and Therapeutic Potential”

Jeffrey Miller, University of Minnesota

“Tumor Genomics: Biology and Implications for Cellular Therapies”

Catherine Wu, Dana-Farber Cancer Institute

9:45AM – 10:15AM

Break

SESSION 2: AUTOLOGOUS STEM CELL TRANSPLANTATION: RELAPSE PREVENTION USING NOVEL AGENTS AND IMMUNOMODULATORY STRATEGIES

10:15AM – 11:45PM

“Epidemiology, Prevention and Treatment of Myeloma Relapse”

Parameswaran Hari, Medical College of Wisconsin

“Challenges in Designing Cancer Vaccines as Effective Immunotherapy”

David Avigan, Beth Israel Deaconess Medical Center

“NK Cell Immunogenetics: Implications for Relapse Risk and Prevention”

Katharine Hsu, Memorial Sloan-Kettering Cancer Center

11:45PM – 1:45PM **Lunch Break and Poster Viewing** (Authors present 12:45-1:45PM)

SESSION 3: RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: PREVENTION AND TREATMENT

1:45PM – 3:15PM **“Preemptive and Maintenance Strategies to Prevent Relapse after Allogeneic SCT”**

Marcos de Lima, Case Western Reserve University

“Adjunctive Strategies to Improve Cell Therapy for Relapse”

Christoph Schmid, University of Augsburg

“Improving Graft-versus-Tumor: Strategies to Enhance T Cell Function”

David Porter, University of Pennsylvania

3:15PM – 3:30PM **Break**

SESSION 4: PROTOCOL PLANNING COMMITTEE PRESENTATIONS - Part I

3:30PM – 4:15PM **Statistical Challenges in Post-Transplant Relapse Studies**

4:15PM – 5:45PM **Biology Protocol Development Team**

Mitchell Cairo, New York Medical College

John DiPersio, Washington University

Jerry Radich, Fred Hutchinson Cancer Research Center

Prevention Protocol Development Team

David Avigan, Beth Israel Deaconess Medical Center

Marcos de Lima, Case Western Reserve University

Treatment Protocol Development Team

Jeffrey Miller, University of Minnesota

David Porter, University of Pennsylvania

5:45PM – 6:00PM **Break**

6:00PM – 7:30PM **Protocol Planning Breakout Working Groups**

Biology Protocol Development (Room A)

Prevention Protocol Development (Room E1/E2)

Treatment Protocol Development (Room F)

Tuesday, November 6, 2012

SESSION 5: BEST ABSTRACTS

8:00AM – 9:00AM

Oral Presentations from Selected Abstracts

“Pharmacological inhibition of signaling through the VIP receptor decreases leukemia relapse in murine allogeneic BMT recipients”

Edmund Waller, Emory University

“Genetic variations in graft-versus-leukemia reaction pathways and relapse risk after allogeneic hematopoietic stem cell transplantation: an explore study”

He Huang, First Affiliated Hospital, Zhejiang University School of Medicine

“Reversal of T Cell exhaustion in pre-treatment marrow T Cells is associated with effective Graft-Versus-Leukemia responses to donor lymphocyte infusion”

Pavan Bachiredy, Dana-Farber Cancer Institute

“The relationship of acute GVHD and pre- and post- transplant flow-MRD to the incidence and timing of relapse in children undergoing allogeneic transplantation for high risk ALL: defining a target population and window for immunological intervention to prevent relapse”

Michael Pulsipher, University Of Utah

9:00AM – 10:00AM

Young Investigator Awardees - Oral Presentations

“Systematic identification of personal mutated tumor-specific neoantigens in CLL”

Mohini Rajasagi, Dana Farber Cancer Institute

“Autologous whole tumor cell vaccination early after allogeneic stem cell transplantation elicits anti-tumor T cell responses in patients with advanced chronic lymphocytic leukemia (CLL)”

Ute Burkhardt, Dana-Farber Cancer Institute

“CD19 targeted allogeneic EBV-specific T cells for the treatment of relapsed ALL in pediatric patients post HSCT”

Kevin Curran, Memorial Sloan-Kettering Cancer Center

“Donor natural killer cell infusions following non-myeloablative HLA-haploidentical transplantation to augment graft-versus-tumor effects in patients with hematological malignancies”

Monica Thakar, Medical College of Wisconsin

“Azacitidine and donor lymphocyte infusions induce long-term molecular remissions in patients with MDS or AML relapsing after allogeneic hematopoietic stem cell transplantation”

Thomas Schroeder, University Hospital of Duesseldorf

“CD25+ regulatory T cell-depleted donor lymphocyte infusion for relapse after allogeneic transplantation - a phase 1 study”

Sarah Nikiforow, Dana-Farber Cancer Institute

10:00AM – 10:45AM

Best of Poster Session

Ulrike Bacher, Munich Leukemia Laboratory

Nirali Shah, National Cancer Institute

10:45AM – 11:00AM

Break

SESSION 6: PROTOCOL PLANNING COMMITTEE PRESENTATIONS - Part II

11:00AM – 12:00PM

Biology Protocol Development Team

Mitchell Cairo, New York Medical College

John DiPersio, Washington University

Jerry Radich, Fred Hutchinson Cancer Research Center

12:00PM – 1:30PM

Lunch Break and Poster Viewing

1:30PM – 2:30PM

Prevention Protocol Development Team

David Avigan, Beth Israel Deaconess Medical Center

Marcos de Lima, Case Western Reserve University

2:30PM – 3:30PM

Treatment Protocol Development Team

Jeffrey Miller, University of Minnesota

David Porter, University of Pennsylvania

3:30PM – 4:00PM

Meeting Wrap-Up